These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35942725)

  • 1. New antimicrobial treatment options for severe Gram-negative infections.
    Hetzler L; Kollef MH; Yuenger V; Micek ST; Betthauser KD
    Curr Opin Crit Care; 2022 Oct; 28(5):522-533. PubMed ID: 35942725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
    Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and
    Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E
    Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment options for multiresistant gram negatives.
    Paterson DL; Isler B; Stewart A
    Curr Opin Infect Dis; 2020 Apr; 33(2):214-223. PubMed ID: 32068644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
    Ong'uti S; Czech M; Robilotti E; Holubar M
    Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
    Lodise TP; Bassetti M; Ferrer R; Naas T; Niki Y; Paterson DL; Zeitlinger M; Echols R
    Expert Rev Anti Infect Ther; 2022 May; 20(5):707-719. PubMed ID: 34937518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Highly Resistant Gram-Negative Infections in the Intensive Care Unit in the Era of Novel Antibiotics.
    Clancy CJ; Nguyen MH
    Infect Dis Clin North Am; 2022 Dec; 36(4):791-823. PubMed ID: 36328637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
    Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB
    Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections.
    MacVane SH
    J Intensive Care Med; 2017 Jan; 32(1):25-37. PubMed ID: 26772199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developments on antibiotics for multidrug resistant bacterial Gram-negative infections.
    Voulgaris GL; Voulgari ML; Falagas ME
    Expert Rev Anti Infect Ther; 2019 Jun; 17(6):387-401. PubMed ID: 31006284
    [No Abstract]   [Full Text] [Related]  

  • 14. ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery.
    Righi E; Mutters NT; Guirao X; Del Toro MD; Eckmann C; Friedrich AW; Giannella M; Kluytmans J; Presterl E; Christaki E; Cross ELA; Visentin A; Sganga G; Tsioutis C; Tacconelli E
    Clin Microbiol Infect; 2023 Apr; 29(4):463-479. PubMed ID: 36566836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms.
    Koenig C; Kuti JL
    Pharmacotherapy; 2024 Aug; 44(8):658-674. PubMed ID: 38949413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections.
    Jabbour JF; Sharara SL; Kanj SS
    Curr Opin Infect Dis; 2020 Apr; 33(2):146-154. PubMed ID: 32022742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of multidrug-resistant Gram-negative infections in children.
    Hsu AJ; Tamma PD
    Clin Infect Dis; 2014 May; 58(10):1439-48. PubMed ID: 24501388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
    Karakonstantis S; Kritsotakis EI; Gikas A
    Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.